{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.8110","value":"0.832"},{"groupId":"OG001","spread":"0.5703","value":"2.185"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"481"}],"units":"Participants"}],"title":"Abdominal/GI, n=244,481"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.3219","value":"-9.629"},{"groupId":"OG001","spread":"0.9295","value":"-8.217"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"480"}],"units":"Participants"}],"title":"Peripheral Neuropathy, n=244,480"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.3074","value":"-2.521"},{"groupId":"OG001","spread":"0.8803","value":"1.501"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"480"}],"units":"Participants"}],"title":"Hormonal/Menopausal Symptoms, n=244,480"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.8358","value":"-3.023"},{"groupId":"OG001","spread":"0.5581","value":"-2.219"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"480"}],"units":"Participants"}],"title":"Other Chemotherapy Side Effects, n=244,480"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.3690","value":"-20.743"},{"groupId":"OG001","spread":"0.9821","value":"-23.363"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"242"},{"groupId":"OG001","value":"477"}],"units":"Participants"}],"title":"Hair Loss, n=242,477"}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"481"}],"units":"Participants"}],"description":"EORTC-QLQ-OV28 is supplement to EORTC-QLQ-C30. It includes 3 functional scales (body image, sexuality, attitude to disease/treatment) and 5 symptom scales/items (abdominal/GI symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side-effects, and hair loss). Symptoms scales score was calculated by averaging scores of all scale items and transforming average scores linearly (\\[average score minus 1\\] divided by 3\\*100). All of the symptoms scales range in score from 0 to 100. Higher score represents a higher (\"worse\") level of symptoms. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Baseline was defined as the latest pre-dose assessment (Day 1 pre-dose).","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo matching niraparib 300 milligram (mg) (3×100 mg capsules) (fixed dose) once daily (QD) orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received placebo based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kilogram \\[kg\\] and Baseline platelet count \\>=150,000 per microliter \\[μL\\]) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG000","title":"Placebo"},{"description":"Participants received niraparib 300 mg (3×100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight \\>=77 kg and Baseline platelet count \\>=150,000 per μL) or 200 mg (2×100 mg capsules for participants with a Baseline body weight \\<77 kg or Baseline platelet count \\<150,000 per μL).","id":"OG001","title":"Niraparib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT Population. Only those participants with data available at the specified time points were analyzed (represented by n= X in the category titles).","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1, Pre-dose) and Up to 34 months","title":"Change From Baseline in Symptoms Scale of EORTC-QLQ-OV28","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}